TITLE

Exhaled Leukotrienes and prostaglandins in COPD

AUTHOR(S)
Montuschi, P.; Kharitonov, S.A.; Ciabattoni, G.; Barnes, P.J.
PUB. DATE
July 2003
SOURCE
Thorax;Jul2003, Vol. 58 Issue 7, p585
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The role of eicosanoids, including leukotrienes (LTs) and prostaglandins (PGs), in chronic obstructive pulmonary disease (COPD) is uncertain. The aim of this study was to investigate whether eicosanoids are measurable in exhaled breath condensate (EBC), a non-invasive method of collecting airway secretions, in patients with stable mild to moderate COPD, and to show possible differences in their concentrations compared with control subjects. Methods: LTB[sub 4], LTE[sub 4], PGE[sub 2], PGD[sub 2]-methoxime, PGF[sub 2α], and thromboxane B[sub 2] (TxB[sub 2]) were measured in EBC in 15 healthy ex-smokers, 20 steroid naïve patients with COPD who were ex-smokers, and in 25 patients with COPD who were ex-smokers and who were treated with inhaled corticosteroids. The study was of cross sectional design and all subjects were matched for age and smoking habit. Results: LTB[sub 4] and PGE[sub 2] concentrations were increased in steroid naïve (LTB[sub 4]: median 100.6 (range 73.5-145.0) pg/ml, p < 0.001; PGE[sub 2]: 98.0 (range 57.0-128.4) pg/ml, p < 0.001) and steroid treated patients with COPD (LTB[sub 4]: 99.0 (range 57.9-170.5) pg/ml, p < 0.001; PGE[sub 2]: 93.6 (range 52.8-157.0) pg/ml, p < 0.001) compared with control subjects (LTB[sub 4]: 38.1 (range 31.2-53.6) pg/ml; PGE[sub 2]: 44.3 (range 30.2-52.1) pg/ml). Both groups of patients had similar concentrations of exhaled LTB[sub 4] (p = 0.43) and PGE[sub 2] (p = 0.59). When measurable, LTE[sub 4] and PGD[sub 2]-methoxime concentrations were similar in COPD patients and controls, whereas PGF[sub 2α] concentrations were increased in the former. TxB[sub 2]-LI was undetectable in any of the subjects. Conclusions: There is a selective increase in exhaled LTB[sub 4] and PGE[sub 2] in patients with COPD which may be relatively resistant to inhaled corticosteroid therapy.
ACCESSION #
10595437

 

Related Articles

  • Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Biernacki, W.A.; Kharitonov, S.A.; Barnes, P.J. // Thorax;Apr2003, Vol. 58 Issue 4, p294 

    Background: Exacerbations are an important feature of chronic obstructive pulmonary disease (COPD), accounting for a large proportion of health care costs. They are associated with increased airway inflammation and oxidative stress. Methods: Concentrations of leukotriene B4 (LTB4), a marker of...

  • A risk-benefit assessment of antileukotrienes in asthma. Smith, L.J. // Drug Safety;Sep1998, Vol. 19 Issue 3, p205 

    The antileukotriene drugs are the first new therapeutic agents approved for the treatment of asthma in more than 20 years. The currently available compounds are orally active and either prevent the cysteinyl leukotrienes from binding to and activating the cysLT-1 receptor in the lung...

  • Evaluation of Theophylline or Pranlukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, as Add-On Therapy in Uncontrolled Asthmatic Patients with a Medium Dose of Inhaled Corticosteroids. Tsuchida, Tomoko; Matsuse, Hiroto; Machida, Ikuko; Kondo, Yuki; Saeki, Sachiko; Tomari, Shinya; Obase, Yasushi; Matsuo, Nobuko; Shimoda, Terufumi; Kohno, Shigeru // Allergy & Asthma Proceedings;Jul/Aug2005, Vol. 26 Issue 4, p287 

    A few studies compared the additional effects of oral controller medicines on pulmonary function in asthmatic patients on a moderate dose of inhaled steroids. The aim of this study was to compare the additional effects of two oral asthma controllers, a leukotriene receptor antagonist and a...

  • Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Gompertz, S.; Bayley, D. L.; Hill, S. L.; Stockley, R. A. // Thorax;Jan2001, Vol. 56 Issue 1, p36 

    Background: Patients with more frequent exacerbations of chronic obstructive pulmonary disease (COPD) may have increased bronchial inflammation. Airway inflammation was measured in patients who had been thoroughly investigated with full pulmonary function testing, thoracic HRCT...

  • Daclizumab: A Potential Asthma Therapy? Antoniu, Sabina A. // Recent Patents on Inflammation & Allergy Drug Discovery;Nov2010, Vol. 4 Issue 3, p214 

    Airways inflammation in asthma is triggered and maintained by CD4+ (Th2) cells which are activated by IL-2 and stimulate the eosinophilic inflammation, IgE secretion and mucus hyperproduction. Current anti-inflammatory therapies include inhaled corticosteroids, and leukotriene modifiers but they...

  • Vasculitis Induced by Zafirlukast Therapy. Soy, M.; Ozer, H.; Canataroglu, A.; Gumurdulu, D.; Erken, E. // Clinical Rheumatology;Aug2002, Vol. 21 Issue 4, p328 

    : Zafirlukast is a leukotriene inhibitor that has recently been approved for the prophylaxis of asthma. Although this new product has been well accepted because of its convenient dosing and relatively few side effects, several cases of Churg–Strauss syndrome have been reported to be...

  • Evaluation of Second-Line Therapy for Asthma. Miller, Karl E. // American Family Physician;11/1/2001, Vol. 64 Issue 9, p1619 

    Presents information from a study by A.M. Wilson and others that assessed the effectiveness of adding a leukotriene receptor antagonist and a long-acting beta2 antagonist as second-line therapy in the management of asthma. Description of the study and its results; Conclusion that both...

  • ASTHMA.  // Thorax;Dec2001 Supp, Vol. 56, piii72 

    This article presents various studies related to asthma. It is well known that anatomical dead space increases with end-inspiratory lung volume. The gradient of the relationship is regarded as an index of airway distensibility. Between 1-10% of patients on ACEI require discontinuation of therapy...

  • zafirlukast.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1217 

    The article provides information on zafirlukast, a long-term control agent used in the management of asthma. It works by antagonizing the effects of leukotrienes, which are components of slow-reacting substance of anaphylaxis. These substances mediate airway edema, smooth muscle constriction and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics